Research
Cellular
Insulin monotherapy for T2DM treatment increases the risk of major CV events and deaths from HF compared to metformin.
Practitioners should be cautious when prescribing insulin monotherapy for type 2 diabetes due to increased cardiovascular risks.
StrongRefutesmedium confidence
insulin monotherapy for T2DM treatment increases the risk of major CV events and deaths from HF, when compared to metformin.
Why this rating
The claim is supported by comparative studies mentioned in the abstract.
Source
Novel Approaches to the Management of Diabetes Mellitus in Patients withCoronary Artery Disease
Evangelos Oikonomou et al. · Current Pharmaceutical Design · 2023
DOI 10.2174/1381612829666230703161058
reviewCited 10×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Novel antidiabetic medications have demonstrated cardiovascular safety and benefits by reducing major adverse cardiac events, improving heart failure, and decreasing CVD-related mortality.Strong
- Metformin shows CVD protective properties for DM-induced atherosclerotic and macrovascular complications.Strong
Related findings · Cellular
- Athletes aiming to reduce fat mass and preserve FFM should consume protein intakes in the range of ∼1.8-2.7 g kg(-1) d(-1).Strong
- A minimum daily protein intake of ≥1.6 g/kg is necessary to observe significant improvements in muscle mass from whey protein supplementation.Strong
- Most athletes ideally need 1.2 to 2.0 grams/kg of body weight/day of protein, preferably split across 3-4 meals.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →